Citizens JMP raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $38 from $37 and keeps an Outperform rating on the shares. The company reported solid commercial performance in Q2, the analyst tells investors in a research note. The firm says Acadia raised the lower end of the revenue guidance range due to continued Nuplazid strength.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Strong Financial Performance and Promising Outlook Justify Buy Rating
- ACADIA Pharmaceuticals: Balanced Outlook Amid Solid Performance and Future Uncertainties
- Acadia Pharmaceuticals Reports Strong Q2 2025 Growth
- ACADIA Pharmaceuticals: Strong Sales Performance and Growth Potential Drive Buy Rating
- Acadia Pharmaceuticals narrows FY25 revenue view to $1.045B-$1.095B